decitabine (5-aza-2'deoxycytidine)

DRUG4 trials

Sponsors

Astex Pharmaceuticals, Inc.

Conditions

Chronic Myelogenous LeukemiaMyelodysplastic Syndrome

Phase 2

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

CompletedNCT00042003

Astex Pharmaceuticals, Inc.Chronic Myelogenous Leukemia

Start: 2002-07-31Target: 40Updated: 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

CompletedNCT00041990

Astex Pharmaceuticals, Inc.Chronic Myelogenous Leukemia

Start: 2002-07-31Target: 40Updated: 2007-12-17

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

CompletedNCT00042016

Astex Pharmaceuticals, Inc.Chronic Myelogenous Leukemia

Start: 2002-07-31Target: 40Updated: 2009-10-14

Phase 3

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

CompletedNCT00043381

Astex Pharmaceuticals, Inc.Myelodysplastic Syndrome

Start: 2001-04-30End: 2003-04-30Target: 160Updated: 2024-08-02